Antiangiogenic Antibody BD0801 Combined with Immune Checkpoint Inhibitors Achieves Synergistic Antitumor Activity and Affects the Tumor Microenvironment

The anti-cancer activities of BD0801 and its potential synergistic anti-tumor effects when combined with different immunotherapies were assessed by using in vitro assays and in vivo tumor models.